. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Mov Disord. 2019 Jul 30;34(9):1354–1364. doi: 10.1002/mds.27806

Table 4.

Longitudinal relationship between CSF α-syn and PD medications in PD participants

Variable	PD Participants
Variable	Estimate (95% CI)	P Value
Relationship with CSF α-syn levels PD medication use	4.55 (–38.24, 47.34)	0.834
Total LED	0.055 (−0.014, 0.125)	0.118
LED subtotal: dopamine replacement	0.086 (0.016, 0.156)	0.016
LED subtotal: dopamine agonists	−0.155 (−0.341, 0.031)	0.102
Relationship with CSF α-syn levels^a PD medication use	9.60 (−50.80, 69.99)	0.754
Total LED	0.007 (−0.080, 0.094)	0.878
LED subtotal: dopamine replacement	0.040 (−0.046, 0.127)	0.361
LED Subtotal: dopamine agonists	−0.292 (−0.560, −0.024)	0.083

P values are based on the ranks of CSF α-syn levels.

Subset of participants with hemoglobin <200 ng/mL at all time points.

Excludes participants missing hemoglobin values at one or more time points and the 3 PD subjects with outlying/aberrant CSF data.

CI, confidence interval.